Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy.
Castagnola
Elio
E
Dallorso
Sandro
S
Faraci
Maura
M
Morreale
Giuseppe
G
Di Martino
Daniela
D
Cristina
Emilio
E
Scarso
Lucia
L
Lanino
Edoardo
E
D000361:Agammaglobulinemia / Q000209:etiology*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D020031:Epstein-Barr Virus Infections / Q000628:therapy; D004854:Herpesvirus 4, Human / Q000378:metabolism*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000821:virology*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab